1-(4-chlorobutoxy)-4-methoxybenzene | 20744-08-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(4-chlorobutoxy)-4-methoxybenzene
• 英文别名: 4-(4-Methoxy-phenoxy)-butylchlorid；Hydrochinon-methyl-(4-chlor-butyl)-aether；Hydrochinon-methyl-(ω-chlor-n-butyl)-ether；Methyl-δ-chlorbutyl-hydrochinonether
• CAS: 20744-08-5
• 化学式: C₁₁H₁₅ClO₂
• 分子量: 214.692
• InChiKey: SRKRMNNAVDLHPM-UHFFFAOYSA-N

物化性质

• 沸点：
  319.8±22.0 °C(Predicted)
• 密度：
  1.082±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-chlorobutoxy)-4-methoxybenzene 在 potassium carbonate 、 lithium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  Synthesis and Biological Evaluation ofortho-ArylN-Hydroxycinnamides as Potent Histone Deacetylase (HDAC) 8 Isoform-Selective Inhibitors

  摘要：

  AbstractHistone deacetylases (HDACs) are a family of enzymes that play a crucial role in biological process and diseases. In contrast to other isozymes, HDAC8 is uniquely incapable of histone acetylation. In order to delineate its physiological function, we developed HDAC8‐selective inhibitors using knowledge‐based design combined with structural modeling techniques. Enzyme inhibitory analysis demonstrated that some of the resulting compounds (22 b, 22 d, 22 f, and 22 g) exhibited anti‐HDAC8 activity superior to PCI34051, a known HDAC8‐specific inhibitor, with IC50 values in the range of 5–50 nM. Among them, compound 22 d showed antiproliferative effects toward several human lung cancer cell lines (A549, H1299, and CL1‐5); it exhibited cytotoxicity against human lung CL1‐5 cells similar to that of SAHA yet without significant cytotoxicity for normal IMR‐90 cells. Expression profiling of HDAC isoforms in three cancer cell lines indicated that the HDAC8 level in CL1‐5 is higher than that in H1299 and CL1‐1 cells, a result consistent with the differential cytotoxicity of compound 22 d. These results suggest the effectiveness of our design concept, which may lead to a tool compound for studying the specific role of HDAC8 in cellular biological processes.

  DOI：

  10.1002/cmdc.201200300
• 作为产物：
  描述：

  4-甲氧基苯酚 、 1,4-二氯丁烷 在 potassium carbonate 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 以23%的产率得到1-(4-chlorobutoxy)-4-methoxybenzene
  参考文献：
  名称：

  水镁化作用下的铁催化还原环化：一种针对 N-杂环的模块化策略

  摘要：

  通过使用邻位还原环化制备各种N-杂环-乙烯基苯胺，据报道。该反应由廉价且稳定的铁络合物催化，通常在环境温度下发生。转化可能是通过乙烯基的水镁化作用进行的，并通过分子内亲电试剂捕获原位生成的苄基阴离子以形成杂环。这种铁催化的策略被证明具有广泛的适用性，并被用于合成取代的吲哚、羟吲哚和四氢苯并氮杂吲哚酮衍生物。机理研究表明，氢化物转移步骤的可逆性取决于束缚的亲电试剂的反应性。通过正式合成已报道的生物活性化合物和一系列天然产物，进一步证明了我们方法的合成效用。

  DOI：

  10.1002/anie.202106996

文献信息

• Intermediates for the synthesis of benzoxazol- and benzothiazolamine
  申请人：Janssen Pharmaceutica N.V.

  公开号：US05010198A1

  公开（公告）日：1991-04-23

  Benzoxazol- and benzothiazolamine derivatives having anti-anoxic properties which compounds are useful in the treatment of anoxia. These compounds are produced from certain benzoxazol- and benzothizolamine intermediates.

  Benzoxazol和benzothiazolamine衍生物具有抗缺氧特性，这些化合物在缺氧治疗中很有用。这些化合物是从某些Benzoxazol和benzothizolamine中间体产生的。
• Benzoxazol-and benzothiazolamine derivatives, useful as anti-anoxic
  申请人：Janssen Pharmaceutica N.V.

  公开号：US04861785A1

  公开（公告）日：1989-08-29

  Benzoxazol-and benzothiazolamine derivatives having anti-anoxic properties which compounds are useful in the treatment of anoxia.

  苯并噁唑和苯并噻唑胺衍生物具有抗缺氧特性，这些化合物在缺氧治疗中是有用的。
• Substituted anilinic piperidines as MCH selective antagonists
  申请人：Marzabadi R. Mohammad

  公开号：US20070043080A1

  公开（公告）日：2007-02-22

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

  本发明涉及选择性拮抗黑色素浓集激素-1（MCH1）受体的化合物。本发明提供了一种药物组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明提供了一种由本发明化合物的治疗有效量和药学上可接受的载体组成的药物组合物。本发明还提供了一种制备药物组合物的方法，包括将本发明化合物的治疗有效量和药学上可接受的载体组合。
• Chain length effects in paraffins—III
  作者：F. Korte、W. Klein、E.D. Schmid

  DOI：10.1016/s0040-4020(01)82172-4

  日期：1966.1
• Oki,M.; Mutai,K., Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 1969, vol. 25, p. 1941 - 1951
  作者：Oki,M.、Mutai,K.

  DOI：——

  日期：——